Protalix - Public Comps and Valuation Multiples

Protalix Overview

About Protalix

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Founded

1992

HQ

Employees

213

Website

protalix.com

Sectors

Biopharmaceuticals
BioTech

Financials

LTM Revenue $59.4M

Last FY EBITDA $6.5M

EV

$152M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Protalix Financials

As of October 2025, Protalix reported last 12-month revenue of $59.4M.

In the same period, Protalix generated $39.1M in LTM gross profit and $9.1M in net income.

See Protalix valuation multiples based on analyst estimates

Protalix P&L

In the most recent fiscal year, Protalix reported revenue of $53.4M and EBITDA of $6.5M.

Protalix expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Protalix valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$59.4M	XXX	$53.4M	XXX	XXX	XXX
Gross Profit	$39.1M	XXX	$29.1M	XXX	XXX	XXX
Gross Margin	66%	XXX	54%	XXX	XXX	XXX
EBITDA	n/a	XXX	$6.5M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	12%	XXX	XXX	XXX
EBIT	$9.2M	XXX	$3.9M	XXX	XXX	XXX
EBIT Margin	15%	XXX	7%	XXX	XXX	XXX
Net Profit	$9.1M	XXX	$2.9M	XXX	XXX	XXX
Net Margin	15%	XXX	5%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Protalix including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $59.4M. In the most recent fiscal year, Protalix achieved $53.4M in revenue and $6.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$59.4M	Analyst estimates available to subscribers	$53.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$39.1M	Analyst estimates available to subscribers	$29.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	65.8% gross margin	Analyst estimates available to subscribers	54.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$6.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	12.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$9.2M	Analyst estimates available to subscribers	$3.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	15.5% EBIT margin	Analyst estimates available to subscribers	7.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$9.1M	Analyst estimates available to subscribers	$2.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	15.3% net profit margin	Analyst estimates available to subscribers	5.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Protalix

This financial data table provides comprehensive performance metrics for Protalix, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Protalix generated $59.4M in revenue over the last twelve months.
Gross profit for the last twelve months was $39.1M.
Net income over the last twelve months reached $9.1M.

Fiscal Year Performance

In the most recent fiscal year, Protalix reported $53.4M in total revenue.
Fiscal year EBITDA was $6.5M.
The company maintained a gross profit margin of 54.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 12.2%.
Net profit margin reached 5.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Protalix. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Protalix Stock Performance

Protalix has current market cap of $180M, and EV of $152M.

Market Cap Evolution

Protalix Stock Data

As of October 31, 2025, Protalix's stock price is $2.

See Protalix trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$152M	$180M	XXX	XXX	XXX	XXX	$0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Protalix Valuation Multiples

Protalix's trades at 2.8x EV/Revenue multiple, and 23.3x EV/EBITDA.

See valuation multiples for Protalix and 15K+ public comps

Protalix Financial Valuation Multiples

As of October 31, 2025, Protalix has market cap of $180M and EV of $152M.

Equity research analysts estimate Protalix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Protalix has a P/E ratio of 19.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$180M	XXX	$180M	XXX	XXX	XXX
EV (current)	$152M	XXX	$152M	XXX	XXX	XXX
EV/Revenue	2.6x	XXX	2.8x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	23.3x	XXX	XXX	XXX
EV/EBIT	16.6x	XXX	38.8x	XXX	XXX	XXX
EV/Gross Profit	3.9x	XXX	n/a	XXX	XXX	XXX
P/E	19.8x	XXX	61.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	20.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Protalix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Protalix Margins & Growth Rates

Protalix's last 12 month revenue growth is 66%

Protalix's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Protalix's rule of 40 is 86% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Protalix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Protalix and other 15K+ public comps

Protalix Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	66%	XXX	41%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	12%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	86%	XXX	79%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	47%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial